Sekar Kathiresan
Co-Founder and CEO; Verve Therapeutics · Vanderbilt University Medical Center
Credentials: · · ·
History
- Present
- 2000–2003
Cardiovascular Disease
- 1997–2000
Internal Medicine
- 1993–1997
Research
Analysis of protein-coding genetic variation in 60,706 humans
Nature · 2016 · 8,007 citations
Age-related clonal hematopoiesis associated with adverse outcomes
New England Journal of Medicine · 2014 · 3,992 citations
Genetic studies of body mass index yield new insights for obesity biology
Systematic review or meta-analysis · Nature · 2015 · 3,482 citations
- CO
82 papers
75 papers
67 papers
- AK
64 papers · 20 as a fellow
60 papers · 13 as a fellow
59 papers
- DA
49 papers
47 papers
Grants
- 2016–2022
Data and Research Support Center
NIH Office of the Director · U2C
PI · $55.9M · Vanderbilt University Medical Center
- 2016–2022
Center for Common Disease Genetics
National Human Genome Research Institute · UM1
PI · $91.2M · Broad Institute, Inc.
- 2015–2020
Using Genetic Variation to Study Biology of Blood Lipids & Coronary Heart Disease
National Heart, Lung, and Blood Institute · R01
PI · $3.2M · Boston University Medical Campus
- 2014–2019
Systematic Cell-Based Functional Screening for LDL and Triglyceride Genes
National Heart, Lung, and Blood Institute · R33
Contact PI · $1.6M · Massachusetts General Hospital
Clinical trials
- 2018–2020
Principal investigator · Completed
Massachusetts General Hospital